Eculizumab as an emergency treatment for adult patients with severe COVID-19 in the intensive care unit: A proof-of-concept study

BACKGROUND: Complement pathway inhibition may provide benefit for severe acute respiratory illnesses caused by viral infections such as COVID-19. We present results from a nonrandomized proof-of-concept study of complement C5 inhibitor eculizumab for treatment of severe COVID-19. METHODS: All patien...

Descripción completa

Detalles Bibliográficos
Autores principales: Annane, Djillali, Heming, Nicholas, Grimaldi-Bensouda, Lamiae, Frémeaux-Bacchi, Véronique, Vigan, Marie, Roux, Anne-Laure, Marchal, Armance, Michelon, Hugues, Rottman, Martin, Moine, Pierre
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2020
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7644240/
https://www.ncbi.nlm.nih.gov/pubmed/33173853
http://dx.doi.org/10.1016/j.eclinm.2020.100590

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7644240/
https://www.ncbi.nlm.nih.gov/pubmed/33173853
http://dx.doi.org/10.1016/j.eclinm.2020.100590

Ejemplares similares